The Roche group has raised its guidance for 2019 after sales of its new multiple sclerosis, haemophilia and cancer medicines more than offset a drop in income from the legacy breast cancer drug Herceptin and the autoimmune and cancer medicine Rituxan. Group sales are expected to show a mid to high-single-digit percentage increase this year, measured at constant exchange rates.
